Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.74
PDLI's Cash-to-Debt is ranked lower than
81% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. PDLI: 1.74 )
Ranked among companies with meaningful Cash-to-Debt only.
PDLI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 1.89 Max: No Debt
Current: 1.74
Equity-to-Asset 0.61
PDLI's Equity-to-Asset is ranked lower than
56% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PDLI: 0.61 )
Ranked among companies with meaningful Equity-to-Asset only.
PDLI' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.93  Med: 0.61 Max: 0.98
Current: 0.61
-1.93
0.98
Interest Coverage 2.92
PDLI's Interest Coverage is ranked lower than
88% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PDLI: 2.92 )
Ranked among companies with meaningful Interest Coverage only.
PDLI' s Interest Coverage Range Over the Past 10 Years
Min: 2.92  Med: 14 Max: 20.34
Current: 2.92
2.92
20.34
Piotroski F-Score: 4
Altman Z-Score: 2.01
Beneish M-Score: -0.82
WACC vs ROIC
5.43%
3.69%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 29.27
PDLI's Operating Margin % is ranked higher than
96% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. PDLI: 29.27 )
Ranked among companies with meaningful Operating Margin % only.
PDLI' s Operating Margin % Range Over the Past 10 Years
Min: 29.27  Med: 93.26 Max: 94.93
Current: 29.27
29.27
94.93
Net Margin % 8.02
PDLI's Net Margin % is ranked higher than
91% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. PDLI: 8.02 )
Ranked among companies with meaningful Net Margin % only.
PDLI' s Net Margin % Range Over the Past 10 Years
Min: -9.36  Med: 55.26 Max: 59.61
Current: 8.02
-9.36
59.61
ROE % 2.00
PDLI's ROE % is ranked higher than
85% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. PDLI: 2.00 )
Ranked among companies with meaningful ROE % only.
PDLI' s ROE % Range Over the Past 10 Years
Min: -4.32  Med: 72.89 Max: 1166.18
Current: 2
-4.32
1166.18
ROA % 1.30
PDLI's ROA % is ranked higher than
86% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. PDLI: 1.30 )
Ranked among companies with meaningful ROA % only.
PDLI' s ROA % Range Over the Past 10 Years
Min: -1.8  Med: 38.25 Max: 77.05
Current: 1.3
-1.8
77.05
ROC (Joel Greenblatt) % 85.70
PDLI's ROC (Joel Greenblatt) % is ranked higher than
96% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. PDLI: 85.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PDLI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 50.13  Med: 2574.8 Max: 673588.24
Current: 85.7
50.13
673588.24
3-Year Revenue Growth Rate -19.60
PDLI's 3-Year Revenue Growth Rate is ranked lower than
74% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. PDLI: -19.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PDLI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -19.6  Med: 14.4 Max: 65.5
Current: -19.6
-19.6
65.5
3-Year EBITDA Growth Rate -31.80
PDLI's 3-Year EBITDA Growth Rate is ranked lower than
83% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. PDLI: -31.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PDLI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 14.4 Max: 433.7
Current: -31.8
0
433.7
3-Year EPS without NRI Growth Rate -38.30
PDLI's 3-Year EPS without NRI Growth Rate is ranked lower than
84% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. PDLI: -38.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PDLI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 11.3 Max: 798.3
Current: -38.3
0
798.3
GuruFocus has detected 8 Warning Signs with PDL BioPharma Inc $PDLI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PDLI's 30-Y Financials

Financials (Next Earnings Date: 2017-08-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

PDLI Guru Trades in Q2 2016

Jeremy Grantham 2,853,102 sh (+16.12%)
First Eagle Investment 2,800 sh (unchged)
Paul Tudor Jones Sold Out
Barrow, Hanley, Mewhinney & Strauss 297,175 sh (-0.36%)
Jim Simons 12,565,654 sh (-1.25%)
Joel Greenblatt 2,293,523 sh (-38.56%)
» More
Q3 2016

PDLI Guru Trades in Q3 2016

Paul Tudor Jones 90,300 sh (New)
Jim Simons 13,472,854 sh (+7.22%)
Barrow, Hanley, Mewhinney & Strauss 299,285 sh (+0.71%)
First Eagle Investment 2,800 sh (unchged)
Jeremy Grantham 2,295,234 sh (-19.55%)
Joel Greenblatt 1,266,121 sh (-44.80%)
» More
Q4 2016

PDLI Guru Trades in Q4 2016

Paul Tudor Jones 292,400 sh (+223.81%)
First Eagle Investment 2,800 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 297,626 sh (-0.55%)
Jim Simons 12,875,700 sh (-4.43%)
Jeremy Grantham 1,070,509 sh (-53.36%)
Joel Greenblatt 29,531 sh (-97.67%)
» More
Q1 2017

PDLI Guru Trades in Q1 2017

Charles Brandes 58,578 sh (New)
First Eagle Investment 2,800 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons 12,036,754 sh (-6.52%)
Paul Tudor Jones 213,284 sh (-27.06%)
Barrow, Hanley, Mewhinney & Strauss 25,387 sh (-91.47%)
Jeremy Grantham 63,997 sh (-94.02%)
» More
» Details

Insider Trades

Latest Guru Trades with PDLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:NAS:OVID, NAS:NSTG, NAS:MRUS, NAS:BSTC, NAS:CLDX, NAS:RXDX, NAS:CYAD, OTCPK:PTCHF, NAS:MCRB, OTCPK:THERF, NAS:ASMB, NAS:OTIC, NAS:AVDL, NAS:AGEN, AMEX:BTX, NAS:CCXI, NAS:ADXS, NAS:BLCM, NAS:MYOK, NAS:ARNA » details
Traded in other countries:PDL.Germany,
Headquarter Location:USA
PDL BioPharma Inc is engaged in the discovery of a new generation of targeted treatments for cancer & immunologic diseases. It focuses on intellectual property asset management, investing in new royalty bearing assets & maximizing value of its patent.

PDL discovers and develops humanized monoclonal antibodies and receives royalties from nine marketed products licensed under PDL patents. The ESP Pharma acquisition brought marketed products to PDL in 2005, but because of a lack of strategic fit, PDL sold its commercial assets in early 2008. After paying a special dividend to shareholders, PDL has spun off its drug-discovery and -development business and plans to continue distributing royalty-based income to shareholders.

Ratios

vs
industry
vs
history
PE Ratio 25.45
PDLI's PE Ratio is ranked higher than
92% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. PDLI: 25.45 )
Ranked among companies with meaningful PE Ratio only.
PDLI' s PE Ratio Range Over the Past 10 Years
Min: 1.46  Med: 5.36 Max: 120
Current: 25.45
1.46
120
Forward PE Ratio 6.91
PDLI's Forward PE Ratio is ranked higher than
61% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. PDLI: 6.91 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 25.45
PDLI's PE Ratio without NRI is ranked higher than
93% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. PDLI: 25.45 )
Ranked among companies with meaningful PE Ratio without NRI only.
PDLI' s PE Ratio without NRI Range Over the Past 10 Years
Min: 1.46  Med: 5.18 Max: 130.55
Current: 25.45
1.46
130.55
Price-to-Owner-Earnings 9.05
PDLI's Price-to-Owner-Earnings is ranked higher than
87% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. PDLI: 9.05 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PDLI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.33  Med: 6.02 Max: 70.2
Current: 9.05
1.33
70.2
PB Ratio 0.51
PDLI's PB Ratio is ranked higher than
98% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. PDLI: 0.51 )
Ranked among companies with meaningful PB Ratio only.
PDLI' s PB Ratio Range Over the Past 10 Years
Min: 0.43  Med: 2.83 Max: 38.99
Current: 0.51
0.43
38.99
PS Ratio 2.01
PDLI's PS Ratio is ranked higher than
91% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. PDLI: 2.01 )
Ranked among companies with meaningful PS Ratio only.
PDLI' s PS Ratio Range Over the Past 10 Years
Min: 0.82  Med: 3.02 Max: 15.85
Current: 2.01
0.82
15.85
Price-to-Free-Cash-Flow 6.90
PDLI's Price-to-Free-Cash-Flow is ranked higher than
94% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. PDLI: 6.90 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PDLI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.51  Med: 5.3 Max: 390.6
Current: 6.9
1.51
390.6
Price-to-Operating-Cash-Flow 6.84
PDLI's Price-to-Operating-Cash-Flow is ranked higher than
94% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. PDLI: 6.84 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PDLI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.51  Med: 5.8 Max: 55.87
Current: 6.84
1.51
55.87
EV-to-EBIT 3.75
PDLI's EV-to-EBIT is ranked higher than
84% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. PDLI: 3.75 )
Ranked among companies with meaningful EV-to-EBIT only.
PDLI' s EV-to-EBIT Range Over the Past 10 Years
Min: 0.8  Med: 3.8 Max: 110.3
Current: 3.75
0.8
110.3
EV-to-EBITDA 2.80
PDLI's EV-to-EBITDA is ranked higher than
86% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. PDLI: 2.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
PDLI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.8  Med: 3.6 Max: 19.8
Current: 2.8
0.8
19.8
Shiller PE Ratio 2.04
PDLI's Shiller PE Ratio is ranked higher than
92% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 53.05 vs. PDLI: 2.04 )
Ranked among companies with meaningful Shiller PE Ratio only.
PDLI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 1.81  Med: 10.62 Max: 167.4
Current: 2.04
1.81
167.4
Current Ratio 1.98
PDLI's Current Ratio is ranked lower than
61% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. PDLI: 1.98 )
Ranked among companies with meaningful Current Ratio only.
PDLI' s Current Ratio Range Over the Past 10 Years
Min: 0.26  Med: 10 Max: 76.07
Current: 1.98
0.26
76.07
Quick Ratio 1.96
PDLI's Quick Ratio is ranked lower than
58% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. PDLI: 1.96 )
Ranked among companies with meaningful Quick Ratio only.
PDLI' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 10 Max: 76.07
Current: 1.96
0.26
76.07
Days Inventory 88.37
PDLI's Days Inventory is ranked higher than
68% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. PDLI: 88.37 )
Ranked among companies with meaningful Days Inventory only.
PDLI' s Days Inventory Range Over the Past 10 Years
Min: 88.37  Med: 129.48 Max: 129.48
Current: 88.37
88.37
129.48
Days Sales Outstanding 245.07
PDLI's Days Sales Outstanding is ranked lower than
92% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. PDLI: 245.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
PDLI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.19  Med: 0.9 Max: 245.07
Current: 245.07
0.19
245.07
Days Payable 990.47
PDLI's Days Payable is ranked higher than
97% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. PDLI: 990.47 )
Ranked among companies with meaningful Days Payable only.
PDLI' s Days Payable Range Over the Past 10 Years
Min: 629.97  Med: 629.97 Max: 990.47
Current: 990.47
629.97
990.47

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.16
PDLI's Dividend Yield % is ranked higher than
91% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.05 vs. PDLI: 2.16 )
Ranked among companies with meaningful Dividend Yield % only.
PDLI' s Dividend Yield % Range Over the Past 10 Years
Min: 2.08  Med: 7.91 Max: 20.55
Current: 2.16
2.08
20.55
Dividend Payout Ratio 0.56
PDLI's Dividend Payout Ratio is ranked higher than
63% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. PDLI: 0.56 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PDLI' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.34 Max: 0.56
Current: 0.56
0.26
0.56
3-Year Dividend Growth Rate -45.00
PDLI's 3-Year Dividend Growth Rate is ranked lower than
89% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. PDLI: -45.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PDLI' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -45
Current: -45
5-Year Yield-on-Cost % 0.60
PDLI's 5-Year Yield-on-Cost % is ranked lower than
58% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. PDLI: 0.60 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PDLI' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.58  Med: 2.2 Max: 5.71
Current: 0.6
0.58
5.71
3-Year Average Share Buyback Ratio -5.80
PDLI's 3-Year Average Share Buyback Ratio is ranked higher than
70% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. PDLI: -5.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PDLI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.9  Med: -5.65 Max: -0.1
Current: -5.8
-7.9
-0.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 5.80
PDLI's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. PDLI: 5.80 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PDLI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.1  Med: 5.22 Max: 71.33
Current: 5.8
1.1
71.33
Price-to-Tangible-Book 1.57
PDLI's Price-to-Tangible-Book is ranked higher than
64% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. PDLI: 1.57 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PDLI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.86  Med: 2.92 Max: 47.78
Current: 1.57
0.86
47.78
Price-to-Intrinsic-Value-Projected-FCF 0.13
PDLI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
99% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. PDLI: 0.13 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PDLI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.13  Med: 3.12 Max: 90.82
Current: 0.13
0.13
90.82
Price-to-Median-PS-Value 0.68
PDLI's Price-to-Median-PS-Value is ranked higher than
79% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. PDLI: 0.68 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PDLI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.33  Med: 3.51 Max: 30.17
Current: 0.68
0.33
30.17
Price-to-Graham-Number 1.34
PDLI's Price-to-Graham-Number is ranked higher than
86% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. PDLI: 1.34 )
Ranked among companies with meaningful Price-to-Graham-Number only.
PDLI' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.34  Med: 2.27 Max: 14.85
Current: 1.34
0.34
14.85
Earnings Yield (Greenblatt) % 26.68
PDLI's Earnings Yield (Greenblatt) % is ranked higher than
95% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. PDLI: 26.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PDLI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.9  Med: 26.1 Max: 119.5
Current: 26.68
0.9
119.5
Forward Rate of Return (Yacktman) % 50.56
PDLI's Forward Rate of Return (Yacktman) % is ranked higher than
98% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 16.45 vs. PDLI: 50.56 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PDLI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8.7  Med: 6.5 Max: 74.1
Current: 50.56
-8.7
74.1

More Statistics

Revenue (TTM) (Mil) $186.6
EPS (TTM) $ 0.09
Beta0.63
Short Percentage of Float7.97%
52-Week Range $1.93 - 3.77
Shares Outstanding (Mil)161.77

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 182 142 210
EPS ($) 0.34 0.20 0.29
EPS without NRI ($) 0.34 0.20 0.29
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PDLI

Headlines

Articles On GuruFocus.com
LENSAR® And PDL BioPharma Complete Strategic Financial Restructuring Of LENSAR May 11 2017 
PDL BioPharma Announces First Quarter 2017 Financial Results May 03 2017 
PDL BioPharma to Announce First Quarter 2017 Financial Results on May 3, 2017 Apr 26 2017 
PDL BioPharma Announces Settlement of Keytruda Patent Infringement Lawsuit with Merck Apr 24 2017 
PDL BioPharma to Hold Annual Meeting of Stockholders on June 9, 2017 Apr 06 2017 
8 High-Yield Stocks With Falling Prices Feb 21 2017 
Medical Companies Offer Good Value Opportunities Sep 16 2016 
Undervalued Companies With Growing EPS Apr 04 2016 
Cash is Flowing Nicely for These Five Stocks Aug 19 2015 
Context Capital Management's Top Buys in Q2 2015 Jul 15 2015 

More From Other Websites
LENSAR® And PDL BioPharma Complete Strategic Financial Restructuring Of LENSAR May 11 2017
Edited Transcript of PDLI earnings conference call or presentation 3-May-17 8:30pm GMT May 06 2017
LENSAR® Receives FDA Clearances for Laser Cataract Platform Integration With OCULUS Pentacam®... May 05 2017
PDL BioPharma posts 1Q profit May 03 2017
PDL BioPharma Announces First Quarter 2017 Financial Results May 03 2017
Investor Network: PDL BioPharma, Inc. to Host Earnings Call May 03 2017
PDL BioPharma, Inc. – Value Analysis (NASDAQ:PDLI) : April 26, 2017 Apr 26 2017
PDL BioPharma to Announce First Quarter 2017 Financial Results on May 3, 2017 Apr 26 2017
PDL BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : PDLI-US : April 25,... Apr 25 2017
ETFs with exposure to PDL BioPharma, Inc. : April 24, 2017 Apr 24 2017
Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers Apr 24 2017
PDL BioPharma to be paid $19.5 million by Merck to settle Keytruda patent suit Apr 24 2017
PDL BioPharma Announces Settlement of Keytruda Patent Infringement Lawsuit with Merck Apr 24 2017
PDL BioPharma to Hold Annual Meeting of Stockholders on June 9, 2017 Apr 06 2017
PDL BioPharma (PDLI) Up 5.9% Since Earnings Report: Can It Continue? Apr 03 2017
Today's Research Reports on Stocks to Watch: Celldex Therapeutics and PDL BioPharma Mar 31 2017
ETFs with exposure to PDL BioPharma, Inc. : March 27, 2017 Mar 27 2017
PDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
PDL BioPharma to Present at the Oppenheimer 27th Annual Healthcare Conference Mar 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}